Crain's New York1d
Midtown-based drug company inks $150M deal with Novartis
Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...
Schrödinger’s stock pops as it enters collaboration pact with Novartis worth up to $2.5 billion
The companies also have an expanded three-year software agreement that will increase access for Novartis to Schrödinger’s ...
Hosted on MSN1d
Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four ...
Novartis Posts Results Above Estimates, Raises Outlook
Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...
FierceBiotech2d
Novartis pays Schrödinger $150M, bets billions on the back end to form drug discovery pact
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
Schrodinger’s Promising Growth Potential Highlighted by Novartis Partnership and Strong Fundamentals
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
Novartis shines a light on skin disease using testimonials and digital touchpoints
Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will ...
Gulf Times3h
WISH ’24 ends with Qatar in Mena first to join Novartis’ Cardio4cities initiative
Qatar is to adopt the Cardio4cities approach – a data-driven cardiovascular population health initiative – and become the ...
BioSpace16d
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...
Business Insider1d
UBS Sticks to Their Buy Rating for Novartis AG (NOVN)
UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00. According to TipRanks, Weston is ranked #1736 out of 9162 analysts ...